Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

Discover how cold weather can trigger prostate problems in men over 60, including frequent urination, hormonal changes, and ...

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Medical experts share their answers to all your questions on bladder problems, from urinary tract infections to odd urine ...

As she walked into her fitness class, Kim Vopni, 53, felt a familiar wave of embarrassment and frustration. “Not another leak ...

CHRISTMAS can be a hectic time, with the pressure to buy gifts, cook large meals, and travel to see family. But like any time ...

The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa (vibegron), a beta-3 (β3) adrenergic receptor agonist, dosed once-daily (75mg ...

Sumitomo Pharma’s oral treatment for overactive bladder symptoms has won an expanded label from the FDA, and is now approved ...